http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003083227-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-166 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4965 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-166 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4965 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
| filingDate | 2002-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b585d42a224c280e51cc7a8d62813d58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ce1fc92c7bdb86cc24fe912b38531d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c42fc5df430f302b3f6801a0c35ceb9c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d9bb629681151208bebf39b74168a6c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c588741b87e1d0442c1f6924f99a235d |
| publicationDate | 2003-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2003083227-A1 |
| titleOfInvention | Novel combination therapy to treat glaucoma |
| abstract | Provided is a method for modulating, controlling or regulating intraocular pressure and secretion of the aqueous humor of the eye, in particular for treating or reducing elevated intraocular pressure or secretion, e.g., related to glaucomas. Selected combined drug therapy effectively and synergistically modulates intraocular pressure by either (1) double-blocking the uptake step, wherein both transporters in the first (entry step) of aqueous humor formation are blocked or inhibited; or (2) blocking the entry and exit steps, wherein the sodium-hydrogen (Na + /H + ) exchanger underlying the entry step is blocked or inhibited, and also lowering or reducing the activity of the chloride (Cl − ) channels involved in the second (exit) step of aqueous humor formation. By combining the selected drugs or compounds to produce a combined or synergistic modulating effect, control of IOP is achieved at very low concentrations, with fewer adverse side-effects on the patient. Moreover, the selectivity of each component in the combination permits the fluid levels in the intraocular space to be tailored to the individual patient or circumstance. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009148886-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10206813-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11426306-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11253394-B2 |
| priorityDate | 1999-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 180.